Estimands is a topic of ongoing interest and this year’s conference agenda reflects this. Find out more about each of the sessions below...
“Estimands: the journey continues... “ with the Estimands Implementation Working Group (EIWG). This session will include speakers from both industry and regulators and touch on specific strategies for intercurrent events e.g. composite, treatment policy, as well as realizing the benefits of estimands in terms of transparency in reporting and communication of trial results.
The Oncology Estimands SIG will run a session titled “Answers to old questions using the estimand framework” and will illustrate the power of the estimand framework in structuring and answering questions that have been relevant in oncology development for a long time. The session will report on results of various task forces of the oncology estimand working group and cover topics including: embedding standard oncology endpoints such as duration of response and time to response into the estimand framework; patient-reported outcomes; marginal versus conditional estimands; and biomarker subgroups.
There will also be two sessions based on contributed abstracts focusing on estimands in theory and estimand in practice where we can hear experiences from the wider statistical community.
Last, and by no means least, Sue McKendrick, Oliver Keene and David Wright from the EFPIA/EFSPI Estimand Implementation Working Group will lead an interactive and fun role play workshop on estimands. In the workshop different perspectives (patient, clinical, regulatory, health economist and statistician) will be explored to show how a multidisciplinary team can specify estimands in a realistic clinical setting.
As well as sessions during the main conference Dominic Magirr and Björn Bornkamp will present a pre-conference course on Estimand-aligned statistical analyses of clinical trials.